CRISPR Therapeutics (NASDAQ:CRSP) Price Target Raised to $66.00 at Royal Bank of Canada

CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) had its price objective raised by analysts at Royal Bank of Canada from $57.00 to $66.00 in a research note issued to investors on Thursday, Benzinga reports. The brokerage currently has a “sector perform” rating on the stock. Royal Bank of Canada’s target price indicates a potential downside […]

Related Keywords

Blackrock ,Nova Scotia ,Canada ,Jamesr Kasinger ,Samarth Kulkarni ,Cibc World Market Inc ,Blackrock Inc ,Fairfield Bush ,Needham Company ,Morgan Stanley ,York Mellon Corp ,Royal Bank ,Us Bancorp ,Get Free Report ,General Counsel James ,New York Mellon Corp ,Cibc World Market ,World Market ,Crispr Therapeutics ,Nasdaq Crsp ,Crsp ,Medical ,Boost Price Target ,Royal Bank Of Canada ,